Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07095127 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
A Phase 2 study of Immune Thrombocytopenia (ITP), sponsored by Nuvig Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07095127: Recruiting Phase 2 study of Immune Thrombocytopenia (ITP), sponsored by Nuvig Therapeutics.
NCT07095127 is a Phase 2 study of Immune Thrombocytopenia (ITP) that is actively recruiting participants, run by Nuvig Therapeutics. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07095127, a Phase 2 study of Immune Thrombocytopenia (ITP), is actively recruiting participants, sponsored by Nuvig Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.
Conditions Studied
Interventions
- DRUG NVG-2089
Study Locations (1)
New York
- Nuvig Site - Westbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT07095127 shows while recruiting
NCT07095127 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Immune Thrombocytopenia (ITP) appearing as the primary indexed condition, and to 1 intervention - of which NVG-2089 is the first listed.
NCT07095127 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07095127 about?
NCT07095127 is a clinical study titled "Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia". The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is d...
What is the current status of trial NCT07095127?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-09-30. Estimated completion is 2026-12-31.
What conditions does trial NCT07095127 study?
This clinical trial studies the following conditions: Immune Thrombocytopenia (ITP).
What interventions are being tested in trial NCT07095127?
The interventions under investigation include: NVG-2089 (DRUG).
Who is sponsoring clinical trial NCT07095127?
This trial is sponsored by Nuvig Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07095127 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenia (ITP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07095127's enrollment target sits among peer trials
10 1969th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI